Logo image of VINC

VINCERX PHARMA INC (VINC) Stock Fundamental Analysis

NASDAQ:VINC - Nasdaq - US92731L3042 - Common Stock - Currency: USD

0.1  -0.03 (-24.98%)

After market: 0.0639 -0.04 (-36.1%)

Fundamental Rating

2

Taking everything into account, VINC scores 2 out of 10 in our fundamental rating. VINC was compared to 553 industry peers in the Biotechnology industry. The financial health of VINC is average, but there are quite some concerns on its profitability. VINC has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year VINC has reported negative net income.
In the past year VINC has reported a negative cash flow from operations.
VINC had negative earnings in each of the past 5 years.
In the past 5 years VINC always reported negative operating cash flow.
VINC Yearly Net Income VS EBIT VS OCF VS FCFVINC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

VINC has a worse Return On Assets (-375.69%) than 96.12% of its industry peers.
VINC has a worse Return On Equity (-1104.04%) than 82.89% of its industry peers.
Industry RankSector Rank
ROA -375.69%
ROE -1104.04%
ROIC N/A
ROA(3y)-234.12%
ROA(5y)-147.19%
ROE(3y)-531.34%
ROE(5y)-326.68%
ROIC(3y)N/A
ROIC(5y)N/A
VINC Yearly ROA, ROE, ROICVINC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

VINC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VINC Yearly Profit, Operating, Gross MarginsVINC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, VINC has more shares outstanding
VINC has more shares outstanding than it did 5 years ago.
VINC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VINC Yearly Shares OutstandingVINC Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M
VINC Yearly Total Debt VS Total AssetsVINC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -45.83, we must say that VINC is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -45.83, VINC is doing worse than 93.83% of the companies in the same industry.
VINC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -45.83
ROIC/WACCN/A
WACCN/A
VINC Yearly LT Debt VS Equity VS FCFVINC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 1.21 indicates that VINC should not have too much problems paying its short term obligations.
VINC has a Current ratio of 1.21. This is amonst the worse of the industry: VINC underperforms 85.19% of its industry peers.
A Quick Ratio of 1.21 indicates that VINC should not have too much problems paying its short term obligations.
VINC has a worse Quick ratio (1.21) than 84.13% of its industry peers.
Industry RankSector Rank
Current Ratio 1.21
Quick Ratio 1.21
VINC Yearly Current Assets VS Current LiabilitesVINC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for VINC have decreased strongly by -968.78% in the last year.
EPS 1Y (TTM)-968.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1726.09%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

VINC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.65% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y39.41%
EPS Next 2Y40.4%
EPS Next 3Y25.08%
EPS Next 5Y14.65%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VINC Yearly Revenue VS EstimatesVINC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 50M 100M 150M
VINC Yearly EPS VS EstimatesVINC Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

VINC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VINC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VINC Price Earnings VS Forward Price EarningsVINC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VINC Per share dataVINC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

VINC's earnings are expected to grow with 25.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.4%
EPS Next 3Y25.08%

More info and screens

0

5. Dividend

5.1 Amount

VINC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VINCERX PHARMA INC

NASDAQ:VINC (4/22/2025, 8:00:01 PM)

After market: 0.0639 -0.04 (-36.1%)

0.1

-0.03 (-24.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27 2025-03-27/amc
Earnings (Next)05-12 2025-05-12
Inst Owners10.77%
Inst Owner Change-38.6%
Ins Owners8.37%
Ins Owner Change0%
Market Cap523.00K
Analysts82.86
Price Target204 (203900%)
Short Float %0.02%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.99%
Min EPS beat(2)-21.11%
Max EPS beat(2)23.08%
EPS beat(4)2
Avg EPS beat(4)-15.98%
Min EPS beat(4)-141.97%
Max EPS beat(4)76.09%
EPS beat(8)5
Avg EPS beat(8)-4.73%
EPS beat(12)5
Avg EPS beat(12)-7.86%
EPS beat(16)7
Avg EPS beat(16)-3.75%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3233.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-2508.7%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.19
P/tB 0.19
EV/EBITDA N/A
EPS(TTM)-20.2
EYN/A
EPS(NY)-12.24
Fwd EYN/A
FCF(TTM)-5
FCFYN/A
OCF(TTM)-5
OCFYN/A
SpS0
BVpS0.52
TBVpS0.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -375.69%
ROE -1104.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-234.12%
ROA(5y)-147.19%
ROE(3y)-531.34%
ROE(5y)-326.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.21
Quick Ratio 1.21
Altman-Z -45.83
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-968.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1726.09%
EPS Next Y39.41%
EPS Next 2Y40.4%
EPS Next 3Y25.08%
EPS Next 5Y14.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y26.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y35.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.41%
OCF growth 3YN/A
OCF growth 5YN/A